Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Clinical trial NCT03863145 · UNKNOWN

Trial details

NCT number: NCT03863145
Sponsor: Cosmo Technologies Ltd
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Advanced Refractory Solid Tumors Subjects Considered Likely to Respond to CB-03-10

Start date: 2022-06-14
Primary completion: 2026-01-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.